Home » BARDA Exercises $6 Million Option for Aeolus’ Acute Radiation Syndrome Drug
BARDA Exercises $6 Million Option for Aeolus’ Acute Radiation Syndrome Drug
The Biomedical Advanced Research and Development Authority is making use of $6 million worth of contract options with Aeolus in order to take advantage of benefits, such as an IND filing for Aeolus’ AEOL-10150.
Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News
Upcoming Events
-
07May
-
14May
-
30May